Q1 EPS Forecast for CRISPR Therapeutics Decreased by Analyst
CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($1.60) for the quarter, down from their prior forecast of ($1.51). The […]
![Q1 EPS Forecast for CRISPR Therapeutics Decreased by Analyst](https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/crispr-therapeutics-ag-common-shares-logo-1200x675.png&w=240&h=240&zc=2)